Bristol-Myers Squibb's Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia - Argus Press

Bristol-Myers Squibb's Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia  Argus Press

PRINCETON, N.J.--(BUSINESS WIRE)--Jan 2, 2019--Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration ...



Comments

Popular posts from this blog

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News

Analysis: Large pharma companies do little new drug innovation - STAT